PAXIPEM : Multicenter phase II study of axitinib +/- pembrolizumab in first line treatment for patients with locally advanced or metastatic papillary renal cell carcinoma (PRCC)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513986-38-00

Acronym

ET21-023

Enrollment

Registered

2024-10-02

Start date

2022-06-01

Completion date

Unknown

Last updated

2026-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally advanced or metastatic papillary cell carcinoma (PRCC)

Brief summary

Objective response rate (ORR)

Detailed description

The duration of response (DOR), The best overall response (BOR),, The progression-free survival (PFS),, The overall survival (OS),, The safety according to NCI CTC-AE v5.

Interventions

DRUGAXITINIB

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective response rate (ORR)	—

Secondary

Measure	Time frame
The duration of response (DOR), The best overall response (BOR),, The progression-free survival (PFS),, The overall survival (OS),, The safety according to NCI CTC-AE v5.	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026